

1.1	"Exemption of pharmaceutical products (medicines) ready for use"
-----	--

**Description of the issue**

The special provision 601 refers to the origin of the material, not on the content. That means that it is no more applicable ones the product becomes a waste. In other words, once pharmaceuticals become a waste, they are no longer exempted from the ADR

**Current-Proposed modification of special provision 601 solutions based on the Austrian Multilateral agreement M329 at national level and the agreed wording during the informal meeting dd 0710.2020**

A proposal of Multilateral agreement from Austria M-329

◆ **Austria:** multilateral agreement M329:  
5.2-Medicines

Special provision 601 shall ~~also~~ apply if the pharmaceutical products (medicines, post consumer as pre-consumer) ~~are no longer packed in packagings of a type intended to retail, sale or distribution, or are no longer intended for consumption.~~

~~post-consumer as pre-consumer material~~ encountering the two following conditions:

- final product, packed and ready for distribution/consumption;
- no longer fit for consumption.

**Formatted:** Don't adjust space between Latin and Asian text, Don't adjust space between Asian text and numbers

**Suggested amendment to the ADR:**

~~Austrian proposal for further discussion and consideration~~

**Justification**

- There is no reason to nullify the exemption actually foreseen for pharmaceutical products once they are no more fit for use/sale/consumption but having to be deleted.
- In normal conditions, no increased risk in the waste phase than in the production and consumption phase